Peffault de Latour, R ; Peters, C ; Gibson, B ; Strahm, B ; Lankester, A ; de Heredia, C D ; Longoni, D ; Fioredda, F ; Locatelli, F ; Yaniv, I ; Wachowiak, J 
; Donadieu, J ; Lawitschka, A ; Bierings, M ; Wlodarski, M ; Corbacioglu, S ; Bonanomi, S ; Samarasinghe, S ; Leblanc, T ; Dufour, C ; Dalle, J-H
; Donadieu, J ; Lawitschka, A ; Bierings, M ; Wlodarski, M ; Corbacioglu, S ; Bonanomi, S ; Samarasinghe, S ; Leblanc, T ; Dufour, C ; Dalle, J-H 
Zusammenfassung
Allogeneic hematopoietic stem cell transplantation (HSCT) offers the potential to cure patients with an inherited bone marrow failure syndrome (IBMFS). However, the procedure involves the risk of treatment-related mortality and may be associated with significant early and late morbidity. For these reasons, the benefits should be carefully weighed against the risks. IBMFS are rare, whereas case ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Altmetric